Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific Corporation has received CE Mark approval for its Livian cardiac resynchronization therapy defibrillator, which treats heart failure and helps protect patients at risk of sudden cardiac death.
Subscribe to our email newsletter
The company said that the Livian cardiac resynchronization therapy defibrillator (CRT-D), which is available in high-energy and standard-energy models, enables clinicians to customize therapy based on a patient’s individual needs. Livian also offers clinicians technology to help manage heart failure patients with frequent atrial arrhythmias.
Jim Tobin, president and CEO of Boston Scientific, said: “This next-generation CRT-D offers physicians in Europe and elsewhere even more flexibility for tailoring therapy to each patient. It is a testament to our ongoing commitment to providing innovative solutions for the treatment of heart failure.”